drugset
drugset / Trial / NCT02706132

Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation

NCT02706132 ↗

Phase 1/2 Unknown 15 enrolled Third Affiliated Hospital, Sun Yat-Sen University
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether MSCs are safe and effective in reducing the primary nonfunction (PNF), acute rejection and Ischemic-type Biliary Lesions (ITBLs) morbidity in ABO-incompatible Liver Transplantation.

Timeline

Start
2014-02
Primary completion
2016-12
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1e+06 cells/kg Intravenous

Indications

No indication recorded.